Mack Gene

Mack Gene is listed in filings as CFO and Interim CEO at Gain Therapeutics, Inc.. This profile follows SEC Form 4 activity through Mar 26, 2026, including purchase activity. Recent filings connect the profile to Gain Therapeutics, Inc. (GANX). The current snapshot covers public activity from Aug 12, 2024 to Mar 26, 2026. Reported amounts are shown as $14.5K to $458.0K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.